In the last one month, Sanofi has corrected significantly vis-à-vis its Big Pharma peers. While sector-specific factors have contributed to this negative sentiment, potential fall-out from the Zantac litigations and continued R&D setbacks were the main pain-points. However, there are still plenty of positives to look forward to in this promising equity story, and we believe that this more than warranted correction has opened up an attractive entry point into the French pharma giant. Overall, our ....
